Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Explore
Tags
Search
Path finder
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
irAE guide
Tumour board
Compare
Landscape grid
Rankings
Timeline
Query
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
India deep dive
China deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Complementary and supportive approaches
Hair loss and regrowth
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Completeness
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Open evaluation
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Trials
Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafen

trialsTrialRecruiting

Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafen

aka ECLYPse

A phase 2 trial in colorectal cancer, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, now recruiting.

Overview Connected4

Overview

Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. is a phase 2, interventional study registered as NCT06640166 by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, with a registry enrolment figure of 25 participants, started 2024-06-03 and due to reach its primary completion in 2025-12-31. Interventions recorded: encorafenib + cetuximab + FOLFIRI. Conditions listed: Colorectal Carcinoma; Colorectal Neoplasms; Colorectal Tumor; Colorectal Adenocarcinoma; Colorectal Cancer (CRC); Colorectal Cancer; Colon Cancer; Colon Adenocarcinoma; Colon Carcinoma; Colon Neoplasm. Primary outcome: 6-month Progression Free Survival rate. Colorectal eligibility wording from the registry: "* histologically or cytologically confirmed diagnosis of colorectal adenocarcinoma;". Sites: Italy. No results are recorded here; the registry entry is the source.

Setting

Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.

Phase

Phase 2

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Registry

Enrolled

25 enrolled

Connected

Similar pages

not linked directly; found by shared links

Trial
Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initial
Shares Pierre Fabre, BRAF V600E-mutant colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Trial
Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer
Shares Pierre Fabre, BRAF V600E-mutant colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Trial
A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer
Shares BRAF V600E-mutant colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Trial
A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mutan
Shares BRAF V600E-mutant colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Trial
Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients
Shares BRAF V600E-mutant colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Trial
Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer
Shares BRAF V600E-mutant colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Trial
A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Trial
FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL)
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.

cancers

2

BRAF V600E-mutant colorectal cancer Colon cancer (adenocarcinoma of the colon)

companies

1

terms

1

Colorectal cancer trials open today (registry snapshot)

Evidence strength22/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 2+15
25 enrolled+7
No structured primary endpoint0
Result: recruiting0
No independent replication recorded0

Formula disclosed on the evidence page.

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Sources & links

ClinicalTrials.gov NCT06640166

colorectal-deep-dive

Data

JSON · ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
Report a readout
How review works

Cancers

Colon cancer (adenocarcinoma of the colon)
BRAF V600E-mutant colorectal cancer

Companies

Pierre Fabre

Machine-readable versions of Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafen

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/trials/nct06640166/)
All trials as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id nct06640166.

WebMCP tools registered on this page: onco_search, onco_get_entity.